ISIN: SE0002148817 · Hansa Biopharma AB · © Finansinpektionen

Short Selling Alert: Citadel Advisors LLC

Message date: 5th February 2024

Termsheet of the Shortselling Transaction

As a result of the registered transaction decreased the share of the short position changed from 0,68% to 0,59%. Within the transaction history, this is the 35th adjustment of the short position since the initial commitment of 11th March 2020.
Snapshot transaction history
0,80%
0,71%
0,68%

0,59%

Seven (7) companies specializing in short selling have Hansa Biopharma AB on their short-selling radar. The total share of all short selling positions is 4,61%. The largest share is held by GSA Capital Partners LLP with 0,88%.
Weighting of the position within the overall ranking: 811

Short Selling Radar Europe

Corporate Insights | Information for investors and traders

360°
SSR reporting for: 5th February 2024

Short Selling Radar (Sweden)

Select Country

In this overview, we provide you with visually prepared and enriched with further relevant information short sale holdings for supplementary information and research purposes. The reporting requirements are defined via the specifications of corresponding guidelines and recorded by a publicly accessible register at the Financial Inspections1 . For validation of the data, consult at least a second source.

Tip: If you have a user account with ayondo, you can use the ayondo smart alerts to be notified when net short positionschange, ratings or ad-hoc announcements of listed companies via auto alert.

Short Selling Transaction Report from
5th February 2024

Termsheet of the Shortselling Transaction

As a result of the registered transaction decreased the share of the short position changed from 0,68% to 0,59%. Within the transaction history, this is the 35th adjustment of the short position since the initial commitment of 11th March 2020.
0,80%
0,71%
0,68%

0,59%

Seven (7) companies specializing in short selling have Hansa Biopharma AB on their short-selling radar. The total share of all short selling positions is 4,61%. The largest share is held by GSA Capital Partners LLP with 0,88%.
Weighting of the position within the overall ranking: 811
More info:
Short Selling Transaction Report from
9th January 2024

Termsheet of the Shortselling Transaction

As a result of the registered transaction decreased the share of the short position changed from 0,60% to 0,51%. Within the transaction history, this is the 67th adjustment of the short position since the initial commitment of 7th January 2020.
0,69%
0,58%
0,60%

0,51%

Seven (7) companies specializing in short selling have Hansa Biopharma AB on their short-selling radar. The total share of all short selling positions is 4,61%. The largest share is held by GSA Capital Partners LLP with 0,88%.
Weighting of the position within the overall ranking: 167
More info:
Short Selling Transaction Report from
20th December 2023

Termsheet of the Shortselling Transaction

As a result of the registered transaction decreased the share of the short position changed from 0,90% to 0,88%. Within the transaction history, this is the 8th adjustment of the short position since the initial commitment of 8th September 2023.
0,71%
0,80%
0,90%

0,88%

Seven (7) companies specializing in short selling have Hansa Biopharma AB on their short-selling radar. The total share of all short selling positions is 4,61%. The largest share is held by GSA Capital Partners LLP with 0,88%.
Weighting of the position within the overall ranking: 404
More info:
Short Selling Transaction Report from
6th November 2023

Termsheet of the Shortselling Transaction

As a result of the registered transaction unchanged the share of the short position changed from 0,50% to 0,50%. Within the transaction history, this is the 12th adjustment of the short position since the initial commitment of 2nd June 2021.
0,52%
<0,50%
0,50%

0,50%

Seven (7) companies specializing in short selling have Hansa Biopharma AB on their short-selling radar. The total share of all short selling positions is 4,61%. The largest share is held by GSA Capital Partners LLP with 0,88%.
Weighting of the position within the overall ranking: 835
More info:
Short Selling Transaction Report from
25th August 2023

Termsheet of the Shortselling Transaction

As a result of the registered transaction Increased the share of the short position changed from 0,52% to 0,53%. Within the transaction history, this is the 67th adjustment of the short position since the initial commitment of 1st July 2019.
0,50%
0,50%
0,52%

0,53%

Seven (7) companies specializing in short selling have Hansa Biopharma AB on their short-selling radar. The total share of all short selling positions is 4,61%. The largest share is held by GSA Capital Partners LLP with 0,88%.
Weighting of the position within the overall ranking: 527
More info:
Short Selling Transaction Report from
1st February 2023

Termsheet of the Shortselling Transaction

As a result of the registered transaction Increased the share of the short position changed from 0,71% to 0,81%. Within the transaction history, this is the 24th adjustment of the short position since the initial commitment of 3rd April 2020.
0,58%
0,62%
0,71%

0,81%

Seven (7) companies specializing in short selling have Hansa Biopharma AB on their short-selling radar. The total share of all short selling positions is 4,61%. The largest share is held by GSA Capital Partners LLP with 0,88%.
Weighting of the position within the overall ranking: 197
More info:
Short Selling Transaction Report from
16th September 2022

Termsheet of the Shortselling Transaction

As a result of the registered transaction decreased the share of the short position changed from 0,87% to <0,50%. Within the transaction history, this is the 8th adjustment of the short position since the initial commitment of 25th May 2022.
0,63%
0,71%
0,87%

n/a

<0,50%
Seven (7) companies specializing in short selling have Hansa Biopharma AB on their short-selling radar. The total share of all short selling positions is 4,61%. The largest share is held by GSA Capital Partners LLP with 0,88%.
Weighting of the position within the overall ranking: 790
More info:
Short Selling Transaction Report from
3rd May 2022

Termsheet of the Shortselling Transaction

As a result of the registered transaction decreased the share of the short position changed from 0,50% to <0,50%. Within the transaction history, this is the 51st adjustment of the short position since the initial commitment of 6th November 2018.
0,57%
<0,50%
0,50%

n/a

<0,50%
Seven (7) companies specializing in short selling have Hansa Biopharma AB on their short-selling radar. The total share of all short selling positions is 4,61%. The largest share is held by GSA Capital Partners LLP with 0,88%.
Weighting of the position within the overall ranking: 892
More info:
Short Selling Transaction Report from
22nd March 2022

Termsheet of the Shortselling Transaction

As a result of the registered transaction decreased the share of the short position changed from 0,59% to <0,50%. Within the transaction history, this is the 8th adjustment of the short position since the initial commitment of 30th March 2020.
0,50%
0,60%
0,59%

n/a

<0,50%
Seven (7) companies specializing in short selling have Hansa Biopharma AB on their short-selling radar. The total share of all short selling positions is 4,61%. The largest share is held by GSA Capital Partners LLP with 0,88%.
Weighting of the position within the overall ranking: 917
More info:
Short Selling Transaction Report from
21st October 2021

Termsheet of the Shortselling Transaction

As a result of the registered transaction decreased the share of the short position changed from 0,51% to <0,50%. Within the transaction history, this is the 2nd adjustment of the short position since the initial commitment of 8th October 2021.
-%
-%
0,51%

n/a

<0,50%
Seven (7) companies specializing in short selling have Hansa Biopharma AB on their short-selling radar. The total share of all short selling positions is 4,61%. The largest share is held by GSA Capital Partners LLP with 0,88%.
Weighting of the position within the overall ranking: 1018
More info:
Short Selling Transaction Report from
22nd January 2021

Termsheet of the Shortselling Transaction

As a result of the registered transaction decreased the share of the short position changed from 0,59% to <0,50%. Within the transaction history, this is the 2nd adjustment of the short position since the initial commitment of 11th January 2021.
-%
-%
0,59%

n/a

<0,50%
Seven (7) companies specializing in short selling have Hansa Biopharma AB on their short-selling radar. The total share of all short selling positions is 4,61%. The largest share is held by GSA Capital Partners LLP with 0,88%.
Weighting of the position within the overall ranking: 1123
More info:
Short Selling Transaction Report from
27th April 2020

Termsheet of the Shortselling Transaction

As a result of the registered transaction decreased the share of the short position changed from 0,58% to <0,50%. Within the transaction history, this is the 20th adjustment of the short position since the initial commitment of 4th October 2019.
0,79%
0,69%
0,58%

n/a

<0,50%
Seven (7) companies specializing in short selling have Hansa Biopharma AB on their short-selling radar. The total share of all short selling positions is 4,61%. The largest share is held by GSA Capital Partners LLP with 0,88%.
Weighting of the position within the overall ranking: 1264
More info:
Short Selling Transaction Report from
27th November 2019

Termsheet of the Shortselling Transaction

As a result of the registered transaction decreased the share of the short position changed from 0,51% to <0,50%. Within the transaction history, this is the 20th adjustment of the short position since the initial commitment of 31st January 2019.
0,50%
<0,50%
0,51%

n/a

<0,50%
Seven (7) companies specializing in short selling have HANSA BIOPHARMA AB on their short-selling radar. The total share of all short selling positions is 4,61%. The largest share is held by GSA Capital Partners LLP with 0,88%.
Weighting of the position within the overall ranking: 1348
More info:
Short Selling Transaction Report from
15th November 2018

Termsheet of the Shortselling Transaction

Opened a short position in this security on 15th November 2018. This is the short seller's first exposure with respect to this company.
-%
-%
-%

0,79%

Seven (7) companies specializing in short selling have HANSA MEDICAL AB on their short-selling radar. The total share of all short selling positions is 4,61%. The largest share is held by GSA Capital Partners LLP with 0,88%.
Weighting of the position within the overall ranking: 170
More info:
More related information
Type Total Last Made by Go to
Equity Story 0 - - EQS
Corporate Research 0 - - Corporate Research
Directors Dealings 0 - - DD
Short Seller (DE) 0 - - SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Note

The information prepared here is for informational purposes. The source data comes from the authority responsible for publication - the Swedish Financial Market Supervisory Authority Finansinspektionen (FI). Before further inclusion, e.g. in investment or investment decisions, validation via another source is recommended.


Please note that once positions fall below the 0.50% threshold, they are not reported again until the level triggering the reporting obligation is reached again. It is not apparent from the register data what the % value of the <0.50% position is. This is not updated as is the case with the Federal Gazette, for example. If a short position falls below the reporting threshold, the value is shown as n/a.

Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.